(KRYS) Krystal Biotech - Ratings and Ratios

Krystal Biotech, Inc. is a commercial-stage biotechnology company specializing in the discovery, development, manufacturing, and commercialization of genetic medicines to address severe, unmet medical needs. Its lead product, VYJUVEK (beremagene geperpavec-svdt, or B-VEC), is the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB), a rare and debilitating skin disorder. Beyond VYJUVEK, the company has a robust pipeline of investigational therapies, including KB105 for autosomal recessive congenital ichthyosis, KB104 for Netherton syndrome, KB407 for cystic fibrosis, KB408 for Alpha-1 antitrypsin deficiency, and KB707 for anti-PD-1 relapsed/refractory cancers. Additionally, KB301 is in Phase 2 trials for aesthetic skin conditions, while ophthalmic B-VEC is being explored for ocular complications of DEB. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech leverages its proprietary gene delivery platform to develop transformative treatments for rare and serious diseases.

Over the next three months, KRYS is expected to trade within a range influenced by its technical and fundamental indicators. With a current price of 168.06 and SMAs of 169.64 (20-day) and 175.77 (50-day), the stock may experience resistance near the 50-day SMA. The ATR of 9.15 suggests moderate volatility, potentially keeping the price within a 160-175 range. Fundamentally, the companys market cap of $4.87B, P/E of 56.19, and forward P/E of 22.42 indicate a premium valuation with expectations of future growth. The P/S ratio of 16.77 reflects strong revenue potential, while the RoE of 9.42% signals improving profitability. These factors collectively suggest a stable to slightly bullish outlook for KRYS in the near term.